Ectodermal dysplasias: New perspectives on the treatment of so far immedicable genetic disorders
- PMID: 36147498
- PMCID: PMC9485875
- DOI: 10.3389/fgene.2022.1000744
Ectodermal dysplasias: New perspectives on the treatment of so far immedicable genetic disorders
Abstract
The past decade has witnessed an expansion of molecular approaches facilitating the differential diagnosis of ectodermal dysplasias, a group of genetic diseases characterized by the lack or malformation of hair, teeth, nails, and certain eccrine glands. Moreover, advances in translational research have increased the therapeutic opportunities for such rare diseases, and new dental, surgical, and ophthalmic treatment options are likely to offer relief to many individuals affected by ectodermal dysplasias. In X-linked hypohidrotic ectodermal dysplasia (XLHED), the genetic deficiency of the signaling molecule ectodysplasin A1 (EDA1) may even be overcome before birth by administration of a recombinant replacement protein. This has been shown at least for the key problem of male subjects with XLHED, the nearly complete absence of sweat glands and perspiration which can lead to life-threatening hyperthermia. Prenatal treatment of six boys by injection of an EDA1 replacement protein into the amniotic fluid consistently induced the development of functional sweat glands. Normal ability to sweat has so far persisted for >5 years in the two oldest boys treated in utero. Thus, timely replacement of a missing protein appears to be a promising therapeutic strategy for the most frequent ectodermal dysplasia and possibly additional congenital disorders.
Keywords: ectodermal dysplasia; ectodysplasin A; molecular therapy; neonatal Fc receptor; prosthodontic rehabilitation; stem cell; tissue-engineering.
Copyright © 2022 Schneider.
Conflict of interest statement
HS is inventor on a patent related to the prenatal treatment of XLHED. He signed, however, a Remuneration Waiver Agreement with the Free State of Bavaria to relinquish any personal financial gain from this invention.
Figures


Similar articles
-
Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia.Genes (Basel). 2023 Jan 6;14(1):153. doi: 10.3390/genes14010153. Genes (Basel). 2023. PMID: 36672894 Free PMC article.
-
A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement.Int J Mol Sci. 2023 Apr 12;24(8):7155. doi: 10.3390/ijms24087155. Int J Mol Sci. 2023. PMID: 37108325 Free PMC article.
-
Functional and clinical analysis of five EDA variants associated with ectodermal dysplasia but with a hard-to-predict significance.Front Genet. 2022 Jul 18;13:934395. doi: 10.3389/fgene.2022.934395. eCollection 2022. Front Genet. 2022. PMID: 35923710 Free PMC article.
-
Future developments in XLHED treatment approaches.Am J Med Genet A. 2014 Oct;164A(10):2433-6. doi: 10.1002/ajmg.a.36499. Epub 2014 Mar 26. Am J Med Genet A. 2014. PMID: 24678015 Review.
-
Hypohidrotic ectodermal dysplasia: clinical and molecular review.Int J Dermatol. 2018 Aug;57(8):965-972. doi: 10.1111/ijd.14048. Epub 2018 May 31. Int J Dermatol. 2018. PMID: 29855039 Review.
Cited by
-
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED): A Case Report and Overview of the Diagnosis and Multidisciplinary Modality Treatments.Cureus. 2023 Jun 13;15(6):e40383. doi: 10.7759/cureus.40383. eCollection 2023 Jun. Cureus. 2023. PMID: 37456454 Free PMC article.
-
Attitudes of female carriers of X-linked hypohidrotic ectodermal dysplasia towards prenatal treatment and their decisions during a pregnancy with a male fetus.Orphanet J Rare Dis. 2025 Apr 15;20(1):182. doi: 10.1186/s13023-025-03710-7. Orphanet J Rare Dis. 2025. PMID: 40234959 Free PMC article.
-
Ectodermal Dysplasia - An Overview and Update.Indian Dermatol Online J. 2024 Apr 23;15(3):405-414. doi: 10.4103/idoj.idoj_599_23. eCollection 2024 May-Jun. Indian Dermatol Online J. 2024. PMID: 38845644 Free PMC article. Review.
-
Genetic profiling and diagnostic strategies for patients with ectodermal dysplasias in Korea.Orphanet J Rare Dis. 2024 Sep 7;19(1):329. doi: 10.1186/s13023-024-03331-6. Orphanet J Rare Dis. 2024. PMID: 39244550 Free PMC article.
-
Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia.Genes (Basel). 2023 Jan 6;14(1):153. doi: 10.3390/genes14010153. Genes (Basel). 2023. PMID: 36672894 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous